%0 Journal Article %T Case Report: Interferon-γ Restores Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) in Severe COVID-19 With Acquired Immunosuppression Syndrome %+ Ecotaxie, microenvironnement et développement lymphocytaire (EMily (UMR_S_1160 / U1160)) %A Dickel, Steffen %A Grimm, Clemens %A Amschler, Katharina %A Schnitzler, Sebastian, Uwe %A Schanz, Julie %A Moerer, Onnen %A Payen, Didier %A Tampe, Bjoern %A Winkler, Martin, Sebastian %< avec comité de lecture %@ 1664-3224 %J Frontiers in Immunology %I Frontiers %V 12 %P 645124 %8 2021 %D 2021 %R 10.3389/fimmu.2021.645124 %K SARS-CoV-2 %K COVID-19 %K monocytic human leukocyte antigen receptor %K interferon-y %K intensive care %K acute respiratory distress syndrome %K acquired immunosuppression syndrome %K case report %Z Life Sciences [q-bio]/Human health and pathology/Infectious diseases %Z Life Sciences [q-bio]/Human health and pathology/Emerging diseases %Z Life Sciences [q-bio]/Immunology/Adaptive immunology %Z Life Sciences [q-bio]/Immunology/Innate immunity %Z Life Sciences [q-bio]/Immunology/ImmunotherapyJournal articles %X Background The major histocompatibility complex (MHC) class II characterized by monocytes CD14+ expression of human leukocyte antigen receptors (HLA-DR), is essential for the synapse between innate and adaptive immune response in infectious disease. Its reduced expression is associated with a high risk of secondary infections in septic patients and can be safely corrected by Interferon-y (IFNy) injection. Coronavirus disease (COVID-19) induces an alteration of Interferon (IFN) genes expression potentially responsible for the observed low HLA-DR expression in circulating monocytes (mHLA-DR).Methods We report a case of one-time INFy injection (100 mcg s.c.) in a superinfected 61-year-old man with COVID-19–associated acute respiratory distress syndrome (ARDS), with monitoring of mHLA-DR expression and clinical tolerance.Observations Low mHLA-DR pretreatment expression (26.7%) was observed. IFNy therapy leading to a rapid increase in mHLA-DR expression (83.1%).Conclusions Severe ARDS in a COVID-19 patient has a deep reduction in mHLA-DR expression concomitantly with secondary infections. The unique IFNy injection was safe and led to a sharp increase in the expression of mHLA-DR. Based on immune and infection monitoring, more cases of severe COVID-19 patients with low mHLA-DR should be treated by IFNy to test the clinical effectiveness. %G English %2 https://u-paris.hal.science/hal-03243515/document %2 https://u-paris.hal.science/hal-03243515/file/fimmu-12-645124.pdf %L hal-03243515 %U https://u-paris.hal.science/hal-03243515 %~ UNIV-PARIS %~ UNIVERSITE-PARIS %~ UP-SANTE